NEW YORK and BOSTON, May 6, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, is proud to announce the opening of its office in Boston, Massachusetts. A significant portion of the operations being built by Keryx to support the potential launch of Zerenex in the United States, including commercial, regulatory, medical affairs, legal, public affairs and pharamacovigilance, will be based in Boston.
"Boston is a biopharmaceutical hub with an exceptional pool of talent with relevant experience, which we believe makes it an ideal place to build a top-notch commercial stage organization," said Greg Madison, Chief Operating Officer of Keryx.
For the past few months, as the company prepared its Boston office for occupancy, Keryx's Boston-based staff have been meeting in District Hall, a public innovation space located in the Seaport District of Boston that is run by the Venture Café Foundation. To support District Hall and the important role it plays in facilitating innovation in Boston, the Company is becoming a sponsor of District Hall.Mr. Madison added, "We would like to thank The Venture Café Foundation and the team at District Hall for hosting us during this very important time. Our sponsorship reflects our appreciation of the critical role a public space like District Hall can play in helping companies of all shapes and sizes through times of transitions and in bringing innovative minds together in a collaborative environment." Nicole Fichera of District Hall and the Venture Café Foundation said, "We are happy to welcome Keryx to the neighborhood, and thrilled that they have decided to sponsor our space. Partnerships like this one between Keryx and District Hall really demonstrate the supportive nature of Boston's innovation community. When different parts of the ecosystem support each other, we build a stronger network for everyone."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts